Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Neal D Shore¹, Thomas B Powles², Jens Bedke³, Matthew D Galsky⁴, Joan Palou Redorta⁵, Ja Hyeon Ku⁶, Michal Kretkowski⁷, Evanguelos Xylinas⁸, Boris Alekseev⁹, Dingwei Ye¹⁰, Félix Guerrero-Ramos¹¹, Alberto Briganti¹², Girish S Kulkarni¹³, Julia Brinkmann¹⁴, Anna-Maria Calella¹⁵, Rossano Cesari¹⁶, Anthony Eccleston¹⁷, Elisabete Michelon¹⁸, Jennifer Vermette¹⁹, Caimiao Wei²⁰, Gary D Steinberg²¹

Affiliations

¹ START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com.
² Barts Health Biomedical NIHR Research Centre, Queen Mary University of London, London, UK.
³ Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany.
⁴ The Tisch Cancer Institute, Mount Sinai, New York, NY, USA.
⁵ Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁶ Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
⁷ Clinical Research Center, Spolka z Ograniczona, Poznań, Poland.
⁸ Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Paris, France.
⁹ P. Hertsen Moscow Cancer Research Institute, Moscow, Russia.
¹⁰ Fudan University Shanghai Cancer Center, Shanghai, China.
¹¹ Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.
¹² Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
¹³ Division of Urology, Department of Surgery, Princess Margaret Cancer, Center University of Toronto, Toronto, ON, Canada.
¹⁴ Pfizer Pharma GmbH, Berlin, Germany.
¹⁵ Pfizer SRL, Rome, Italy.
¹⁶ Pfizer SRL, Milan, Italy.
¹⁷ Pfizer Ltd., Tadworth, UK.
¹⁸ Pfizer Inc., New York, NY, USA.
¹⁹ Pfizer Inc., Cambridge, MA, USA.
²⁰ Pfizer Inc., Groton, CT, USA.
²¹ Department of Urology, Rush University Medical Center, Chicago, IL, USA.

PMID: 40691368
PMCID: PMC12353840
DOI: 10.1038/s41591-025-03894-2

Published Erratum

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Neal D Shore et al. Nat Med. 2025 Aug.

. 2025 Aug;31(8):2815.

doi: 10.1038/s41591-025-03894-2.

Authors

Affiliations

¹ START Carolinas/Carolina Urologic Research Center, Myrtle Beach, SC, USA. nshore@auclinics.com.
² Barts Health Biomedical NIHR Research Centre, Queen Mary University of London, London, UK.
³ Department of Urology & Transplantation Surgery, Eva Mayr-Stihl Cancer Center, Klinikum Stuttgart, Stuttgart, Germany.
⁴ The Tisch Cancer Institute, Mount Sinai, New York, NY, USA.
⁵ Department of Urology, Fundació Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
⁶ Department of Urology, Seoul National University Hospital, Seoul, Republic of Korea.
⁷ Clinical Research Center, Spolka z Ograniczona, Poznań, Poland.
⁸ Department of Urology, Bichat-Claude Bernard Hospital, AP-HP, Université de Paris Cité, Paris, France.
⁹ P. Hertsen Moscow Cancer Research Institute, Moscow, Russia.
¹⁰ Fudan University Shanghai Cancer Center, Shanghai, China.
¹¹ Department of Urology, Hospital Universitario 12 de Octubre, Madrid, Spain.
¹² Division of Experimental Oncology/Unit of Urology, Urological Research Institute (URI), IRCCS San Raffaele Scientific Institute, Milan, Italy.
¹³ Division of Urology, Department of Surgery, Princess Margaret Cancer, Center University of Toronto, Toronto, ON, Canada.
¹⁴ Pfizer Pharma GmbH, Berlin, Germany.
¹⁵ Pfizer SRL, Rome, Italy.
¹⁶ Pfizer SRL, Milan, Italy.
¹⁷ Pfizer Ltd., Tadworth, UK.
¹⁸ Pfizer Inc., New York, NY, USA.
¹⁹ Pfizer Inc., Cambridge, MA, USA.
²⁰ Pfizer Inc., Groton, CT, USA.
²¹ Department of Urology, Rush University Medical Center, Chicago, IL, USA.

PMID: 40691368
PMCID: PMC12353840
DOI: 10.1038/s41591-025-03894-2

No abstract available

PubMed Disclaimer

Erratum for

Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial.
Shore ND, Powles TB, Bedke J, Galsky MD, Palou Redorta J, Ku JH, Kretkowski M, Xylinas E, Alekseev B, Ye D, Guerrero-Ramos F, Briganti A, Kulkarni GS, Brinkmann J, Calella AM, Cesari R, Eccleston A, Michelon E, Vermette J, Wei C, Steinberg GD. Shore ND, et al. Nat Med. 2025 Aug;31(8):2806-2814. doi: 10.1038/s41591-025-03738-z. Epub 2025 May 31. Nat Med. 2025. PMID: 40450141 Free PMC article. Clinical Trial.

Publication types

Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Affiliations

Author Correction: Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial

Authors

Affiliations

Erratum for

Publication types